A Multi-center Phase II Study of R-ESHAP Followed by Autologous Transplantation as Salvage Treatment for Patients With Refractory or Relapsed Diffuse Large B-cell Lymphoma.
The standard treatment in patients with refractory or relapsed diffuse large B-cell lymphoma
is salvage chemotherapy followed by autologous transplantation for responsive patients.
However, the standard of salvage chemotherapy remains uncertain. This study is to evaluate
the efficacy and safety of R-ESHAP regimen in a multi-center basis.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
Ye Guo, MD
China: Ethics Committee